Drug intelligence / Profile preview

Thenyldiamine

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Topical, Intranasal, Ophthalmic

Overview

Thenyldiamine is a first-generation antihistamine of the ethylenediamine class with anticholinergic properties. It acts primarily as an H1-antihistamine by interfering with the agonist action of histamine at the Histamine H1 receptor. This mechanism attenuates inflammatory processes and is used to treat conditions such as allergic rhinitis caused by the common cold. Like other first-generation antihistamines, it readily crosses the blood-brain barrier and can cause sedation and central nervous system effects. Thenyldiamine has also been reported to have some use in asthma and bronchitis[1][3][4][5].

Other names: thenyldiaminetenfidilthefanilthenfadiltenildiaminathenyldiaminum

Targets

mAChR (Muscarinic acetylcholine receptors)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Thenyldiamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Thenyldiamine.

Explore the full profile